Patent classifications
A
HUMAN NECESSITIES
Load children
A61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
Load children
A61K
PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
Load children
47/00
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
Load children Filter patents View analytics View as hierarchy Open in page
A61K47/50
the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
Load children Filter patents View analytics View as hierarchy Open in page
A61K47/51
the non-active ingredient being a modifying agent
Load children Filter patents View analytics View as hierarchy Open in page
A61K47/68
the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Load children Filter patents View analytics View as hierarchy Open in page
A61K47/6891
Pre-targeting systems involving an antibody for targeting specific cells
Load children Filter patents View analytics View as hierarchy Open in page
A61K47/6895
Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
Filter patents View analytics View as hierarchy Open in page

A61K47/6895

ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES AND FOLFIRI
20230087871 · 2023-03-23 ·

The present invention concerns antibody-conjugates comprising an anti-CEACAM5-antibody for use for treating cancer in combination with folinic acid, 5-fluoro-uracil and irinotecan (FOLFIRI). The invention further relates to pharmaceutical compositions and kit-of-parts comprising an anti-CEACAM5-antibody in combination with folinic acid, 5-fluoro-uracil and irinotecan (FOLFIRI) for use for treating cancer.

NEPRILYSIN INHIBITORS
20180105503 · 2018-04-19 · ·

In one aspect, the invention relates to compounds having the formula:

##STR00001##

where R.sup.1, R.sup.2, R.sup.3, X, R.sup.4, R.sup.5, and R.sup.6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

Neprilysin inhibitors
09771337 · 2017-09-26 · ·

In one aspect, the invention relates to compounds having the formula: ##STR00001##
where R.sup.1, R.sup.2, R.sup.3, X, R.sup.4, R.sup.5, and R.sup.6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

NEPRILYSIN INHIBITORS
20170088526 · 2017-03-30 · ·

In one aspect, the invention relates to compounds having the formula:

##STR00001##

where R.sup.1, R.sup.2, R.sup.3, X, R.sup.4, R.sup.5, and R.sup.6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.